2025
Treatment of Endometriosis Patients with Selective Estrogen Receptor Modulator & Conjugated Estrogen Negatively Impacts Microvascular Function
Williams A, Content V, Stachenfeld N, Alexander L. Treatment of Endometriosis Patients with Selective Estrogen Receptor Modulator & Conjugated Estrogen Negatively Impacts Microvascular Function. Physiology 2025, 40: 1102. DOI: 10.1152/physiol.2025.40.s1.1102.Peer-Reviewed Original ResearchFlow-mediated dilationNO-mediated dilationBrachial artery diameterEndometriosis patientsConjugated estrogensCardiovascular diseaseVasoprotective actionsEndothelial dysfunctionEndothelial functionArtery diameterHot flashesNG-nitro-L-arginine methyl esterNitric oxide (NO)-mediated vasodilationInduce endothelium-dependent vasodilationIncreasing doses of acetylcholineNG-nitro-L-arginineTreatment of endometriosis patientsEstrogen receptor-bVasculature of womenIntradermal microdialysis fibersMacrovascular endothelial functionEndothelium-dependent vasodilationEstrogen receptor modulatorsFemale-specific risk factorsMicrovascular endothelial dysfunction
2022
Contemporary Use of Hormonal Therapy in Endometrial Cancer: a Literature Review
Kailasam A, Langstraat C. Contemporary Use of Hormonal Therapy in Endometrial Cancer: a Literature Review. Current Treatment Options In Oncology 2022, 23: 1818-1828. PMID: 36417148, DOI: 10.1007/s11864-022-01031-6.Peer-Reviewed Original ResearchConceptsHormone receptor-positiveRecurrent endometrial cancerLow-grade diseaseHormone therapyEndometrial cancerReceptor-positiveSurgical candidatesTreatment optionsGonadotropin-releasing hormone agonistHormone treatmentLevonorgestrel intrauterine deviceSecond-line treatmentHormonal treatment optionsEstrogen receptor modulatorsAnti-estrogen treatmentEndometrial cancer treatmentLow performance statusStandard of careOral progesteroneUpfront settingMetastatic diseaseIntrauterine deviceProgesterone receptorPerformance statusHormone agonistClinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor-Positive Breast Cancer.
Tsuji J, Li T, Grinshpun A, Coorens T, Russo D, Anderson L, Rees R, Nardone A, Patterson C, Lennon NJ, Cibulskis C, Leshchiner I, Tayob N, Tolaney SM, Tung N, McDonnell DP, Krop IE, Winer EP, Stewart C, Getz G, Jeselsohn R. Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor-Positive Breast Cancer. Clinical Cancer Research 2022, 28: 5066-5078. PMID: 36215125, PMCID: PMC9722539, DOI: 10.1158/1078-0432.ccr-22-2305.Peer-Reviewed Original ResearchConceptsProgression-free survivalPhase Ib/II studyCombination of palbociclibBreast cancerWhole-exome sequencingESR1 mutationsII studyClinical efficacySafety profileHormone receptor-positive/HER2-negative advanced breast cancerAdvanced hormone receptor-positive breast cancerHER2-negative advanced breast cancerHormone receptor-positive breast cancerThird-generation selective estrogen receptor modulatorMedian progression-free survivalEndocrine-resistant breast cancerReceptor-positive breast cancerShorter progression-free survivalSelective estrogen receptor modulatorsClinical benefit rateAcceptable safety profileAdvanced breast cancerEstrogen receptor modulatorsSelective ER degraderDNA whole-exome sequencing
2021
Molecular mechanisms of estrogen action in female genital tract development
Alderman MH, Taylor HS. Molecular mechanisms of estrogen action in female genital tract development. Differentiation 2021, 118: 34-40. PMID: 33707128, PMCID: PMC8073215, DOI: 10.1016/j.diff.2021.01.002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsGene expressionSelective estrogen receptor modulatorsFemale genital tract developmentAberrant CpG methylationGenital tract developmentHistone modificationsEpigenetic regulationOrgan developmentCpG methylationTranscriptional pathwaysSpecific fetalEpigenetic modulationMolecular mechanismsFemale reproductive tractLate organogenesisHormonal regulationOrganogenesisEstrogen receptor modulatorsTract developmentReproductive tractIndependent fashionRegulationDisease statesEstrogen actionReceptor modulators
2019
Clinical Application of Teriparatide in Fracture Prevention: A Systematic Review.
Chen Y, Liu R, Hettinghouse A, Wang S, Liu G, Liu C. Clinical Application of Teriparatide in Fracture Prevention: A Systematic Review. JBJS Reviews 2019, 7: e10. PMID: 30694878, DOI: 10.2106/jbjs.rvw.18.00052.Peer-Reviewed Original ResearchConceptsNonvertebral fracturesParathyroid hormoneFracture preventionOsteoporotic patientsSystematic reviewSelective estrogen receptor modulatorsChronic kidney diseaseSystematic Reviews 2Estrogen receptor modulatorsPostmenopausal statusAdverse eventsRANKL inhibitorGlucocorticoid treatmentOvid EmbaseCochrane LibraryKidney diseaseFracture riskEligible studiesStrontium ranelateOvid MEDLINEReceptor modulatorsTeriparatideOsteoporotic individualsHigh riskAnabolic agents
2017
Predictive Biomarkers May allow Precision Therapy of Endometriosis
Hou Z, Mamillapalli R, Taylor HS. Predictive Biomarkers May allow Precision Therapy of Endometriosis. Journal Of Endometriosis And Pelvic Pain Disorders 2017, 9: 279-285. PMID: 35441077, PMCID: PMC9014966, DOI: 10.5301/jeppd.5000311.Peer-Reviewed Original ResearchMedroxyprogesterone acetatePredictive biomarkersProgesterone receptorEstrogen receptorPrecision therapyEutopic endometrial stromal cellsSelective estrogen receptor modulatorsEffect of bazedoxifeneEndometrial stromal cellsEstrogen receptor modulatorsPathogenesis of endometriosisPrimary eutopic endometrial stromal cellsCommon molecular targetsPRA/BPersonalized medicine approachReverse transcriptase-polymerase chain reaction analysisTranscriptase-polymerase chain reaction analysisBaseline expression levelsPelvic painEndometrial biopsyEndometriosis therapySevere endometriosisProgestin resistanceEndometriosis patientsPR expressionHormonal regulation of the endometrium and the effects of hormonal therapies
Ersoy G, Modi M, Alderman M, Taylor H. Hormonal regulation of the endometrium and the effects of hormonal therapies. 2017, 161-176. DOI: 10.1201/9781315151472-11.ChaptersSelective progesterone receptor modulatorsSelective estrogen receptor modulatorsMenopausal hormone therapyIntrauterine deviceOral contraceptivesMedroxyprogesterone acetateMenstrual cycleReceptor modulatorsGonadotropin-releasing hormone agonistProgesterone receptor modulatorsEstrogen receptor modulatorsHuman menstrual cycleHormonal regulationPractice of obstetricsHormonal therapyHormone therapyMenstrual bleedingEndometrial receptivityHormone agonistTestosterone signalingHormonal treatmentSecretory phaseEmbryo implantationEndometriumProliferative phase
2016
Endometrial Cancer-Associated FGF18 Expression Is Reduced by Bazedoxifene in Human Endometrial Stromal Cells In Vitro and in Murine Endometrium
Flannery CA, Fleming AG, Choe GH, Naqvi H, Zhang M, Sharma A, Taylor HS. Endometrial Cancer-Associated FGF18 Expression Is Reduced by Bazedoxifene in Human Endometrial Stromal Cells In Vitro and in Murine Endometrium. Endocrinology 2016, 157: 3699-3708. PMID: 27267714, PMCID: PMC5045514, DOI: 10.1210/en.2016-1233.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnimalsBasic Helix-Loop-Helix Transcription FactorsCarcinoma, EndometrioidCase-Control StudiesCells, CulturedEndometrial HyperplasiaEndometrial NeoplasmsEndometriumFemaleFibroblast Growth FactorsGene Expression ProfilingHumansIndolesMiceMiddle AgedSelective Estrogen Receptor ModulatorsConceptsStromal cellsPostmenopausal womenHormone therapyEpithelial proliferationFGF18 expressionAntiproliferative effectsSelective estrogen receptor modulatorsHuman endometrial stromal cellsGrowth factorBZA/CEMenopausal hormone therapyEndometrial stromal cellsBreast cancer riskEstrogen receptor modulatorsCD1 female miceE74-like factor 5Normal proliferative endometriumParacrine growth factorPrimary stromal cellsTyrosine kinase receptor 2Fibroblast growth factorEndometrial hyperplasiaEndometrial proliferationEndometrial cancerEndometrial adenocarcinoma
2015
Uptake of exemestane chemoprevention in postmenopausal women at increased risk for breast cancer
Aktas B, Sorkin M, Pusztai L, Hofstatter EW. Uptake of exemestane chemoprevention in postmenopausal women at increased risk for breast cancer. European Journal Of Cancer Prevention 2015, 25: 3-8. PMID: 25642790, PMCID: PMC4885537, DOI: 10.1097/cej.0000000000000124.Peer-Reviewed Original ResearchConceptsCancer prevention clinicSelective estrogen receptor modulatorsPostmenopausal womenEstrogen receptor modulatorsChemoprevention uptakePrevention clinicReceptor modulatorsBreast cancer chemopreventionRetrospective chart reviewSerious side effectsChemoprevention medicationsChemopreventive optionChart reviewMean ageAromatase inhibitorsBreast cancerBone densityStudy populationCancer chemopreventionGeneral populationExemestaneSide effectsChemopreventionClinicWomenEffects of ospemifene on the female reproductive and urinary tracts
Archer DF, Carr BR, Pinkerton JV, Taylor HS, Constantine GD. Effects of ospemifene on the female reproductive and urinary tracts. Menopause The Journal Of The North American Menopause Society 2015, 22: 786-796. PMID: 25423325, PMCID: PMC4481022, DOI: 10.1097/gme.0000000000000365.Peer-Reviewed Original ResearchConceptsEstrogen receptor agonist/antagonistReceptor agonists/antagonistsAgonists/antagonistsVaginal atrophyVaginal tissueSelective estrogen receptor modulatorsEffects of ospemifenePostmenopausal women's healthRelief of symptomsEstrogen receptor modulatorsAgonist/antagonist effectsUrinary tract tissuesHormone-responsive tissuesTissue-dependent responseEndometrial histopathologyEndometrial safetyEstrogen therapyClinical effectsTransvaginal ultrasoundMenopausal symptomsUrinary tractPreclinical dataCytologic examinationVaginal effectsPreclinical modelsAtrophic Vaginitis in Breast Cancer Survivors: A Difficult Survivorship Issue
Lester J, Pahouja G, Andersen B, Lustberg M. Atrophic Vaginitis in Breast Cancer Survivors: A Difficult Survivorship Issue. Journal Of Personalized Medicine 2015, 5: 50-66. PMID: 25815692, PMCID: PMC4493485, DOI: 10.3390/jpm5020050.Peer-Reviewed Original ResearchBreast cancer survivorsAtrophic vaginitisCancer survivorsEndocrine therapySelective estrogen receptor modulatorsSystemic estrogen therapyPatient-reported symptomsEstrogen receptor modulatorsVariety of symptomsQuality of lifeVaginal moistureEstrogen therapyLifestyle modificationLocal estrogenTopical estrogenVaginal drynessGynecological examinationSurvivorship issuesGenital skinOvarian failureVaginal dischargeSystematic therapyAromatase inhibitorsReceptor modulatorsBreast cancer
2014
Letrozole Versus Clomiphene for Infertility in the Polycystic Ovary Syndrome
Legro R, Brzyski R, Diamond M, Coutifaris C, Schlaff W, Casson P, Christman G, Huang H, Yan Q, Alvero R, Haisenleder D, Barnhart K, Bates G, Usadi R, Lucidi S, Baker V, Trussell J, Krawetz S, Snyder P, Ohl D, Santoro N, Eisenberg E, Zhang H. Letrozole Versus Clomiphene for Infertility in the Polycystic Ovary Syndrome. Obstetrical & Gynecological Survey 2014, 69: 599-601. DOI: 10.1097/01.ogx.0000456355.64379.77.Peer-Reviewed Original ResearchPolycystic ovary syndromeAdverse effect profileMultiple pregnancy rateEffect profileFertility agentsAromatase inhibitorsLive birthsHigher multiple pregnancy rateLower multiple pregnancy rateSelective estrogen receptor modulatorsMale partnersNormal uterine cavityPatent fallopian tubesPrimary study outcomeCumulative live birthReproductive-age womenGood safety profileEstrogen receptor modulatorsClomiphene groupLetrozole groupClomiphene citrateRotterdam criteriaHot flushesOvary syndromeInfertile womenDifferential effects of menopausal therapies on the endometrium
Mirkin S, Archer DF, Taylor HS, Pickar JH, Komm BS. Differential effects of menopausal therapies on the endometrium. Menopause The Journal Of The North American Menopause Society 2014, 21: 899-908. PMID: 24518153, DOI: 10.1097/gme.0000000000000186.Peer-Reviewed Original ResearchConceptsTissue selective estrogen complexSelective estrogen receptor modulatorsEstrogen-progestin therapyEndometrial profileEndometrial safetyEndometrial effectsEstrogen therapyMenopausal symptomsEstrogen receptor degradationNew hormone therapiesIndividual selective estrogen receptor modulatorsIrregular uterine bleedingIncidence of hyperplasiaEstrogen receptor modulatorsMenopausal therapyTolerability profileUterine bleedingEndometrial proliferationHormone therapyPostmenopausal womenEndometrial cancerClinical findingsSafety profileAvailable treatmentsReceptor modulatorsTreatment with Bazedoxifene and Conjugated Estrogens Results in Regression of Endometriosis in a Murine Model1
Naqvi H, Sakr S, Presti T, Krikun G, Komm B, Taylor HS. Treatment with Bazedoxifene and Conjugated Estrogens Results in Regression of Endometriosis in a Murine Model1. Biology Of Reproduction 2014, 90: 121, 1-7. PMID: 24740602, PMCID: PMC4093999, DOI: 10.1095/biolreprod.113.114165.Peer-Reviewed Original ResearchConceptsTissue selective estrogen complexBZA/CESelective estrogen receptor modulatorsConjugated estrogensLesion sizeEstrogen receptor mRNA expressionFemale CD-1 miceEndometriotic lesion sizeRegression of endometriosisOvarian cyst formationEctopic endometrial lesionsNovel treatment optionsEstrogen receptor modulatorsCD-1 miceReceptor mRNA expressionAction of estrogenMurine Model1Endometrial proliferationEndometrial lesionsUntreated lesionsExperimental endometriosisProgesterone receptorTreatment optionsEstrogen resultsReceptor modulators
2013
Gender and the Prevalence and Progression of Renal Disease
Neugarten J, Golestaneh L. Gender and the Prevalence and Progression of Renal Disease. Advances In Kidney Disease And Health 2013, 20: 390-395. PMID: 23978543, DOI: 10.1053/j.ackd.2013.05.004.Peer-Reviewed Original ResearchConceptsCourse of kidney diseaseKidney diseaseSelective estrogen receptor modulatorsProgression of diabetic nephropathyProgression of renal diseaseProgressive kidney injuryReceptor-dependent mechanismEstrogen receptor modulatorsEffects of estrogenModel of CKDNondiabetic kidney diseaseKidney disease progressionRenin-angiotensin systemCellular processesPostmenopausal womenRegulated genesSignal transductionReceptor modulatorsKidney injuryHormones per seVasoactive agentsExtracellular matrix metabolismHormonal milieuKidney hemodynamicsRenal diseaseTissue Selective Estrogen Complexes (TSECs) Differentially Modulate Markers of Proliferation and Differentiation in Endometrial Cells
Kulak J, Ferriani RA, Komm BS, Taylor HS. Tissue Selective Estrogen Complexes (TSECs) Differentially Modulate Markers of Proliferation and Differentiation in Endometrial Cells. Reproductive Sciences 2013, 20: 129-137. PMID: 23171676, PMCID: PMC3826278, DOI: 10.1177/1933719112463251.Peer-Reviewed Original ResearchConceptsTissue selective estrogen complexSelective estrogen receptor modulatorsLeukemia inhibitory factorProgesterone receptorBazedoxifene acetateEndometrial effectsEndometrial proliferationEstrogen complexEffects of raloxifeneRisk of estrogenVehicle-treated controlsEndometrial cell proliferationEstrogen receptor modulatorsEndometrial gene expressionMessenger RNA expressionDifferential effectsEndometrial safetyEstrogen-responsive genesEndometrial hyperplasiaLIF expressionPR expressionEndometrial cellsReceptor modulatorsMore estrogenIshikawa cells
2012
The Pregnancy in Polycystic Ovary Syndrome II (PPCOS II) trial: Rationale and design of a double-blind randomized trial of clomiphene citrate and letrozole for the treatment of infertility in women with polycystic ovary syndrome
Legro RS, Kunselman AR, Brzyski RG, Casson PR, Diamond MP, Schlaff WD, Christman GM, Coutifaris C, Taylor HS, Eisenberg E, Santoro N, Zhang H, Network F. The Pregnancy in Polycystic Ovary Syndrome II (PPCOS II) trial: Rationale and design of a double-blind randomized trial of clomiphene citrate and letrozole for the treatment of infertility in women with polycystic ovary syndrome. Contemporary Clinical Trials 2012, 33: 470-481. PMID: 22265923, PMCID: PMC3312939, DOI: 10.1016/j.cct.2011.12.005.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic AgentsChi-Square DistributionClomipheneDouble-Blind MethodFemaleFertility Agents, FemaleHealth Status IndicatorsHirsutismHumansHyperandrogenismInfertility, FemaleLetrozoleMiddle AgedNitrilesOvulation InductionPolycystic Ovary SyndromePregnancyQuality of LifeResearch DesignTriazolesWomen's HealthYoung AdultConceptsPolycystic ovary syndromeClomiphene citrateOvary syndromeInfertile womenTreatment armsDouble-blind clinical trialSelective estrogen receptor modulatorsMajor infertility factorOral clomiphene citrateMultiple pregnancy rateFirst-line treatmentLive birth rateEstrogen receptor modulatorsDifferent treatment armsTreatment of infertilityPoor ovulatory responseEndometrial effectsII trialII studyLine treatmentInfertility factorsProgestin withdrawalAromatase inhibitorsClinical trialsFemale infertility
2011
Tamoxifen Induces Rapid, Reversible Atrophy, and Metaplasia in Mouse Stomach
Huh WJ, Khurana SS, Geahlen JH, Kohli K, Waller RA, Mills JC. Tamoxifen Induces Rapid, Reversible Atrophy, and Metaplasia in Mouse Stomach. Gastroenterology 2011, 142: 21-24.e7. PMID: 22001866, PMCID: PMC3708546, DOI: 10.1053/j.gastro.2011.09.050.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAnimalsAtrophyChief Cells, GastricFemaleGene Expression RegulationInjections, IntraperitonealIntegrasesLac OperonMaleMetaplasiaMiceMice, Inbred BALB CMice, Inbred C57BLMice, TransgenicParietal Cells, GastricSelective Estrogen Receptor ModulatorsSpecies SpecificityTamoxifenTime FactorsConceptsSelective estrogen receptor modulatorsParietal cellsBody weight doseEstrogen receptor modulatorsTamoxifen side effectsAcid secretion inhibitionZymogenic chief cellsReversible atrophyWeight doseGastric toxicityIntraperitoneal administrationReceptor modulatorsNormal miceSide effectsSecretion inhibitionGastric parietal cellsChief cellsMouse stomachTamoxifenMetaplasiaMultiple strainsToxicityCellsPatientsAtrophyTreatment with Bazedoxifene, a Selective Estrogen Receptor Modulator, Causes Regression of Endometriosis in a Mouse Model
Kulak J, Fischer C, Komm B, Taylor HS. Treatment with Bazedoxifene, a Selective Estrogen Receptor Modulator, Causes Regression of Endometriosis in a Mouse Model. Endocrinology 2011, 152: 3226-3232. PMID: 21586552, PMCID: PMC3138238, DOI: 10.1210/en.2010-1010.Peer-Reviewed Original ResearchConceptsSelective estrogen receptor modulatorsRegression of endometriosisTreatment of endometriosisEstrogen receptor modulatorsReceptor modulatorsEstrogen-dependent disorderTissue-selective actionSignificant side effectsCD-1 miceEndometrial gene expressionCentral nervous systemEffective novel agentsExpression of PREndometrial stimulationGnRH agonistOvarian enlargementER expressionLIF mRNAExperimental endometriosisEstrogen antagonismER antagonistNovel agentsSERM bazedoxifeneEndometriosisMouse model
2010
SERMs in the prevention and treatment of postmenopausal osteoporosis: an update
Júnior J, Kulak CA, Taylor HS. SERMs in the prevention and treatment of postmenopausal osteoporosis: an update. Archives Of Endocrinology And Metabolism 2010, 54: 200-205. PMID: 20485909, PMCID: PMC3109295, DOI: 10.1590/s0004-27302010000200016.Peer-Reviewed Original ResearchConceptsSelective estrogen receptor modulatorsEstrogen receptor modulatorsEstrogen receptorPostmenopausal osteoporosisReceptor modulatorsClinical developmentIdeal selective estrogen receptor modulatorNew selective estrogen receptor modulatorRelative benefit/riskTissue selective estrogen complexNovel selective estrogen receptor modulatorBenefit/riskMenopausal therapyEstrogen complexSpecific indicationsSingle agentER agonistsAntagonist effectsTarget tissuesOsteoporosisFurther investigationPreventionTreatmentIndicationsOspemifene
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply